Triveni Bio

Triveni Bio company information, Employees & Contact Information

Explore related pages

Related company profiles:

Triveni Bio is a biotech company pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders. The company’s approach establishes proof-of-concept at the earliest stages of drug development. Through a strong understanding of genetics and mechanistic biology, our pipeline is powered for indication expansion where we know we can have the most impact. To learn more, visit www.triveni.bio.

Company Details

Employees
41
Address
99 Coolidge Avenue, Watertown,ma 02472,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Watertown, MA
Looking for a particular Triveni Bio employee's phone or email?

Triveni Bio Questions

News

Triveni Bio Doses First Patient in Phase 2 Trial of TRIV-509 for Atopic Dermatitis - Dermatology Times

Triveni Bio Doses First Patient in Phase 2 Trial of TRIV-509 for Atopic Dermatitis Dermatology Times

Triveni Doses First Subject in Global Phase 2 Proof of Concept Study of TRIV-509 in Atopic Dermatitis, Presents Translational Data at 2025 EADV Congress Demonstrating Novel Biology in Patient Samples - PR Newswire

Triveni Doses First Subject in Global Phase 2 Proof of Concept Study of TRIV-509 in Atopic Dermatitis, Presents Translational Data at 2025 EADV Congress Demonstrating Novel Biology in Patient Samples PR Newswire

Triveni Bio Doses First Healthy Volunteers in Clinical Trial for TRIV-509, Coinciding with Preclinical Data Presentations Further Validating Novel Kallikrein 5/7 Biology in Atopic Dermatitis - Yahoo Finance

Triveni Bio Doses First Healthy Volunteers in Clinical Trial for TRIV-509, Coinciding with Preclinical Data Presentations Further Validating Novel Kallikrein 5/7 Biology in Atopic Dermatitis Yahoo Finance

Triveni Bio Launches First-in-Human Trial for TRIV-509 in Atopic Dermatitis - Dermatology Times

Triveni Bio Launches First-in-Human Trial for TRIV-509 in Atopic Dermatitis Dermatology Times

Renasant Bio launches to develop disease-modifying treatments for ADPKD - BioWorld MedTech

Renasant Bio launches to develop disease-modifying treatments for ADPKD BioWorld MedTech

Wilson Sonsini Advises Goldman Sachs Alternatives on Patent Matters Related to Series B Investment in Triveni Bio - Wilson Sonsini

Wilson Sonsini Advises Goldman Sachs Alternatives on Patent Matters Related to Series B Investment in Triveni Bio Wilson Sonsini

Triveni ropes in $115M series B less than a year after $92M fundraise - Fierce Biotech

Triveni ropes in $115M series B less than a year after $92M fundraise Fierce Biotech

Study Identifies Gut Sensor That Propels Intestines To Move - Harvard Medical School

Study Identifies Gut Sensor That Propels Intestines To Move Harvard Medical School

Triveni emerges from biotech merger with $92M for immune disease drugs - BioPharma Dive

Triveni emerges from biotech merger with $92M for immune disease drugs BioPharma Dive

Triveni Bio lands $115M to move atopic dermatitis bispecific into clinic - FirstWord Pharma

Triveni Bio lands $115M to move atopic dermatitis bispecific into clinic FirstWord Pharma

Local biotech to start testing eczema drug in humans with $115M round - The Business Journals

Local biotech to start testing eczema drug in humans with $115M round The Business Journals

Triveni Bio Appoints Bhaskar Srivastava, M.D., Ph.D., as Chief Medical Officer - citybiz

Triveni Bio Appoints Bhaskar Srivastava, M.D., Ph.D., as Chief Medical Officer citybiz

Dualitas launches with $65M to advance bispecifics for I&I - BioWorld MedTech

Dualitas launches with $65M to advance bispecifics for I&I BioWorld MedTech

Triveni Bio Raises $115 Million Series B Financing to Expand Pipeline of Therapeutics Addressing Immunological and Inflammatory (I&I) Disorders - PR Newswire

Triveni Bio Raises $115 Million Series B Financing to Expand Pipeline of Therapeutics Addressing Immunological and Inflammatory (I&I) Disorders PR Newswire

With $115M more, Triveni accelerates immune drug work - BioPharma Dive

With $115M more, Triveni accelerates immune drug work BioPharma Dive

Dermatology Times May 2025 Recap - Dermatology Times

Dermatology Times May 2025 Recap Dermatology Times

(Bi-)specific gravity: Bambusa, others serious about approach - BioWorld MedTech

(Bi-)specific gravity: Bambusa, others serious about approach BioWorld MedTech

Triveni Bio Launches with $92 Million Series A Financing to Advance Genetics-Informed Precision Medicines for the Treatment of Immunological and Inflammatory (I&I) Disorders - PR Newswire

Triveni Bio Launches with $92 Million Series A Financing to Advance Genetics-Informed Precision Medicines for the Treatment of Immunological and Inflammatory (I&I) Disorders PR Newswire

Triveni Bio Raises $115M Series B - citybiz

Triveni Bio Raises $115M Series B citybiz

Triveni scores $115m to expand immunology pipeline - Pharmaceutical Technology

Triveni scores $115m to expand immunology pipeline Pharmaceutical Technology

Triveni raises $92M for I&I pipeline after Modify, Amagma merger - Fierce Biotech

Triveni raises $92M for I&I pipeline after Modify, Amagma merger Fierce Biotech

Triveni Bio Welcomes Jeff Albers and Allison Luo to its Board of Directors - PR Newswire

Triveni Bio Welcomes Jeff Albers and Allison Luo to its Board of Directors PR Newswire

Triveni Bio raises $92m to take on I&I disorders - BioProcess International

Triveni Bio raises $92m to take on I&I disorders BioProcess International

Triveni Bio Raises $92M in Series A - citybiz

Triveni Bio Raises $92M in Series A citybiz

Triveni Bio Launches with $92M Series A Financing - Pharmaceutical Executive

Triveni Bio Launches with $92M Series A Financing Pharmaceutical Executive

Adimab Provides Update on Pipeline - Business Wire

Adimab Provides Update on Pipeline Business Wire

Triveni Bio launches with $92M Series A to fund eczema antibody treatment - Endpoints News

Triveni Bio launches with $92M Series A to fund eczema antibody treatment Endpoints News

Startups To Help With Eczema - TechRound

Startups To Help With Eczema TechRound

Leading the transformation: Triveni integrates technology, sustainability, and rural empowerment as India eyes global bio-manufacturing hub - ChiniMandi

Leading the transformation: Triveni integrates technology, sustainability, and rural empowerment as India eyes global bio-manufacturing hub ChiniMandi

Biotech Startup Triveni Unveils $92M to Address Barrier to Treating Inflammation - MedCity News

Biotech Startup Triveni Unveils $92M to Address Barrier to Treating Inflammation MedCity News

Seaport Therapeutics Secures $225M for New Kind of Depression Drug - MedCity News

Seaport Therapeutics Secures $225M for New Kind of Depression Drug MedCity News

Beneath the Surface: Why we itch with Brian S. Kim, MD - Healio

Beneath the Surface: Why we itch with Brian S. Kim, MD Healio

The Week’s 10 Biggest Funding Rounds: OpenAI On Top — By A Lot - Crunchbase News

The Week’s 10 Biggest Funding Rounds: OpenAI On Top — By A Lot Crunchbase News

Thermostable lamprey variable lymphocyte receptor antibody for detection of Plasmodium falciparum histidine rich protein-2 - Nature

Thermostable lamprey variable lymphocyte receptor antibody for detection of Plasmodium falciparum histidine rich protein-2 Nature

The Top Five Venture Capital Heavyweights in Life Sciences - Inside Precision Medicine

The Top Five Venture Capital Heavyweights in Life Sciences Inside Precision Medicine

Fierce Biotech Fundraising Tracker '24: AusperBio adds $73M series B; Ottimo raises $140M - Fierce Biotech

Fierce Biotech Fundraising Tracker '24: AusperBio adds $73M series B; Ottimo raises $140M Fierce Biotech

Interim no more: Ashley Magargee to fill Genentech CEO post; Pfizer, Moderna make commercial leadership adjustments - Endpoints News

Interim no more: Ashley Magargee to fill Genentech CEO post; Pfizer, Moderna make commercial leadership adjustments Endpoints News

Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission - Fierce Biotech

Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission Fierce Biotech

Cormorant Launches Second SPAC Following MoonLake Deal with $100M IPO - BioSpace

Cormorant Launches Second SPAC Following MoonLake Deal with $100M IPO BioSpace

Advancing Itch Management With Emerging Therapies and Neuromodulation - HMP Global Learning Network

Advancing Itch Management With Emerging Therapies and Neuromodulation HMP Global Learning Network

Amid piling waste, biomining only hope to clear landfills in Doddaballapur: Study - Deccan Herald

Amid piling waste, biomining only hope to clear landfills in Doddaballapur: Study Deccan Herald

Is TruAlt Bioenergy IPO Ready To Beat Balrampur, Triveni & Dalmia? - IPO Central

Is TruAlt Bioenergy IPO Ready To Beat Balrampur, Triveni & Dalmia? IPO Central

Congratulations: KKK 12 winner Tushar Kalia gets married to partner Triveni Barman - IWMBuzz

Congratulations: KKK 12 winner Tushar Kalia gets married to partner Triveni Barman IWMBuzz

Top Triveni Bio Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant